MFAP2 and gastric adenocarcinoma: We developed a prognostic model for patients with STAD based on COL10A1, MFAP2, CTHRC1, P4HA3, and FAP, and a nomogram to predict the survival rate of patients with STAD at 1, 3, and 5 years.